Singapore markets closed
  • Straits Times Index

    -26.97 (-0.82%)
  • Nikkei

    -11.77 (-0.04%)
  • Hang Seng

    +9.12 (+0.05%)
  • FTSE 100

    +4.81 (+0.06%)

    -2,061.93 (-8.80%)
  • CMC Crypto 200

    -34.34 (-6.34%)
  • S&P 500

    -56.43 (-1.32%)
  • Dow

    -289.69 (-0.85%)
  • Nasdaq

    -265.06 (-2.04%)
  • Gold

    -9.50 (-0.54%)
  • Crude Oil

    +0.61 (+0.67%)
  • 10-Yr Bond

    +0.1120 (+3.89%)
  • FTSE Bursa Malaysia

    -12.18 (-0.80%)
  • Jakarta Composite Index

    -14.12 (-0.20%)
  • PSE Index

    +39.23 (+0.57%)

Bayer more stringent in glyphosate settlement talks due to downturn

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Ludwig Burger

FRANKFURT (Reuters) - Bayer <BAYGn.DE> said the economic downturn and the need to preserve cash means it is taking a tougher stance in talks to settle claims its glyphosate-based weedkillers cause cancer, even as its earnings rose.

The pandemic has significantly slowed the mediation process, the German drugs and pesticides company said in a statement on Monday.

"The company will consider a deal only if it is financially reasonable and puts in place a mechanism to resolve potential future claims efficiently," Chief Executive Werner Baumann said.

"This applies now more than ever," he added, citing a looming recession and considerable liquidity challenges as a result of the coronavirus pandemic.

The number of U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer reached 52,500, up from 48,600 in February, the company added.

Bayer denies claims that Roundup - or its active ingredient glyphosate - cause cancer, saying decades of independent studies have shown it to be safe for human use.

The company said first-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 10.2% to 4.39 billion euros ($4.76 billion), surpassing average analyst expectations of 4.17 billion, according to Refinitiv data.

Bayer, which is due to hold its annual shareholder meeting in a virtual format on Tuesday, warned that it was unable to assess the impact of the pandemic on results this year.

The first-quarter beat was driven by a 14% gain in earnings at the agriculture division from higher sales of crop chemicals and corn seeds. Earnings were further underpinned by a 19% increase in revenue from stroke prevention drug Xarelto.

Bayer also pointed to the stockpiling of drugs as consumers purchased over-the-counter products and patients sought additional prescriptions as a safety net as the coronavirus spread.

Operating cash flow, however, fell to an outflow of 189 million euros, down from an inflow of 1 billion a year earlier, as it brought forward the settlement of agriculture payables and receivables were paid later.

"Despite this good performance, we have a question mark regarding cash-flows," said Bryan Garnier analyst Jean-Jacques Le Fur, also voicing concern about customers' creditworthiness in the farming sector.

Bayer's shares were up 3% at 61.36 euros by 0925 GMT, beating a 2% gain in the wider German market <.GDAXI>.

(Additional reporting by Patricia Weiss; editing by Thomas Seythal, Emma Thomasson, Kirsten Donovan)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting